Skip to main content

Hospital treatment and management in relapse of schizophrenia in the UK: associated costs

  • Janet Munro (a1), Sarah Osborne (a2), Lindsay Dearden (a3), Katie Pascoe (a3), Aline Gauthier (a4) and Martin Price (a3)...
Aims and method

Relapse in schizophrenia carries a heavy burden. This study aimed to describe the characteristics of patients admitted to hospital for relapse and to explore the treatment, length of stay and associated in-patient costs. The sample comprised individuals discharged from a London National Health Service trust following a relapse of schizophrenia. The costs of hospital treatment were obtained by applying referenced unit costs.


The cohort comprised 71 patients. Treatment non-adherence was implicated in 76% of relapses. Mean length of hospital stay was 138.9 days (range 1 week-1.8 years). Mean admission cost was £25 852 (range £1270-120 000). Over 97% of costs were hospital costs and less than 3% drug costs.

Clinical implications

Hospital treatment for relapse of schizophrenia carries a considerable economic burden, as shown in this study. Treatment non-adherence is a significant factor contributing to relapse.

Corresponding author
Janet Munro (
Hide All

Declaration of interest

J.M. and S.O. were employed by King's College London, Institute of Psychiatry and funded by Janssen-Cilag for their work in this project. L.D., K.P. and M.P. are employees of Janssen-Cilag.

Hide All
1 Lamberti, JS. Seven keys to relapse prevention in schizophrenia. J Psychiatr Pract 2001; 7: 253–9.
2 Wiersma, D, Nienhuis, FJ, Slooff, CJ, Giel, R. Natural course of schizophrenic disorders: a 15-year follow up of a Dutch incidence cohort. Schizophr Bull 1998; 24: 7585.
3 McGlashan, TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988; 14: 515–42.
4 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
5 Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–51.
6 Csernansky, JG, Schuchart, EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16: 473–84.
7 Hogarty, GE, Ulrich, RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998; 32: 243–50.
8 Weiden, P, Mott, T, Curcio, N. Recognition and management of neuroleptic noncompliance in schizophrenia. In Contemporary Issues in the Treatment of Schizophrenia (eds Shriqui, CL, Nasrallah, HA): 411–34. American Psychiatric Publishing, 1995.
9 Weiden, PJ, Zygmunt, A. Medication noncompliance in schizophrenia. Part I: Assessment. J Prac Psych Behav Health 1997; 3: 106–10.
10 National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (Technology Appraisal No. 43). NICE, 2002.
11 National Collaborating Centre for Mental Health. Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated Edition) (National Clinical Guideline Number 82). British Psychological Society, Royal College of Psychiatrists, 2010.
12 South London and Maudsley NHS Foundation Trust. Annual report 2004/05. SLAM, 2005 (
13 Curtis, L, Netten, A. Unit costs of Health and Social Care 2006. University of Kent, 2006.
14 British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (issue 52). BMJ Group and Pharm Press, 2006.
15 Office for National Statistics. Census 2001: Lewisham. ONS, 2003 (
16 Singleton, N, Bumpstead, R, O'Brien, M, Lee, A, Meltzer, H. Psychiatric Morbidity among Adults living in Private Households, 2000: Summary Report. Office for National Statistics, 2001.
17 Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7.
18 Kamali, M, Kelly, L, Gervin, M, Browne, S, Larkin, C, O'Callaghan, E. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv 2001; 52: 161–6.
19 Fenton, WS, Blyler, CR, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637–51.
20 Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9.
21 Schooler, NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64 (suppl 16): s147.
22 Knapp, M, King, D, Pugner, K, Lapuerta, P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509–16.
23 Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.
24 Hospital Episode Statistics (HESonline) Primary Diagnosis: 3 Character. HES, 2010 (
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 61 *
Loading metrics...

Abstract views

Total abstract views: 203 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 22nd June 2018. This data will be updated every 24 hours.

Hospital treatment and management in relapse of schizophrenia in the UK: associated costs

  • Janet Munro (a1), Sarah Osborne (a2), Lindsay Dearden (a3), Katie Pascoe (a3), Aline Gauthier (a4) and Martin Price (a3)...
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *